Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf van Heeswijk

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Antimicrobial Agents and Chemotherapy|August 10, 2011
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatinJee Eun Lee, Rolf van Heeswijk, Katia Alves, et al.
Journal of Clinical Pharmacology|November 1, 2011
The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevirVarun Garg, Rolf van Heeswijk, Yijun Yang, et al.
Hepatology (Baltimore, Md.)|May 28, 2011
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimusVarun Garg, Rolf van Heeswijk, Jee Eun Lee, et al.
Antiviral Therapy|July 7, 2009
Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected childrenCharles la Porte, Rolf van Heeswijk, Charles D Mitchell, et al.
Journal of Clinical Microbiology|May 16, 2008
Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207Nacer Lounis, Tom Gevers, Joke Van Den Berg, et al.
AIDS (London, England)|January 1, 2005
Impact of African herbal medicines on antiretroviral metabolismEdward Mills, Brian C Foster, Rolf van Heeswijk, et al.
Antiviral Therapy|August 26, 2009
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapyKeikawus Arastéh, Armin Rieger, Patrick Yeni, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2013
Pharmacokinetic interaction between telaprevir and methadoneRolf van Heeswijk, Peter Verboven, Ann Vandevoorde, et al.
Gastroenterology|June 25, 2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Gastroenterology|November 2, 2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis CPatrick Marcellin, Xavier Forns, Tobias Goeser, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Antimicrobial Agents and Chemotherapy|August 10, 2011
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatinJee Eun Lee, Rolf van Heeswijk, Katia Alves, et al.
Journal of Clinical Pharmacology|November 1, 2011
The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevirVarun Garg, Rolf van Heeswijk, Yijun Yang, et al.
Hepatology (Baltimore, Md.)|May 28, 2011
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimusVarun Garg, Rolf van Heeswijk, Jee Eun Lee, et al.
Antiviral Therapy|July 7, 2009
Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected childrenCharles la Porte, Rolf van Heeswijk, Charles D Mitchell, et al.
Journal of Clinical Microbiology|May 16, 2008
Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207Nacer Lounis, Tom Gevers, Joke Van Den Berg, et al.
AIDS (London, England)|January 1, 2005
Impact of African herbal medicines on antiretroviral metabolismEdward Mills, Brian C Foster, Rolf van Heeswijk, et al.
Antiviral Therapy|August 26, 2009
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapyKeikawus Arastéh, Armin Rieger, Patrick Yeni, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2013
Pharmacokinetic interaction between telaprevir and methadoneRolf van Heeswijk, Peter Verboven, Ann Vandevoorde, et al.
Gastroenterology|June 25, 2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Gastroenterology|November 2, 2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis CPatrick Marcellin, Xavier Forns, Tobias Goeser, et al.
Pageof 2